Evidence map›Paper›PMID 29609636›Full record

ArticleOrphanet journal of rare diseases2018

A perspective on "cure" for Rett syndrome.

Angus John Clarke, Ana Paula Abdala Sheikh

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Protective role of mirtazapine in adult female Mecp2Journal of neurodevelopmental disorders · 2020
    Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Angus John ClarkeInstitute of Medical Genetics, Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, Wales, UK. clarkeaj@cardiff.ac.uk.
Ana Paula Abdala SheikhSchool of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.

Funding

CRCNS: Modeling the respiratory-sympathetic coupling in neurogenic hypertensionR01AT008632 · NCCIH · INDIANA UNIVERSITY INDIANAPOLIS · PI MOLKOV, YAROSLAV · 2015 to 2019
$1.4M
NCCIH NIH HHS R01 AT008632
6 · The paper itself

Abstract

The reversal of the Rett syndrome disease process in the Mecp2 mouse model of Guy et al. (2007) has motivated families and researchers to work on this condition. The reversibility in adult mice suggests that there is potentially much to be gained from rational treatments applied to patients of any age. However, it may be difficult to strike the right balance between enthusiasm on the one hand and realism on the other. One effect of this has been a fragmentation of the "Rett syndrome community" with some groups giving priority to work aimed at a cure while fewer resources are devoted to medical or therapy-based interventions to enhance the quality of life of affected patients or provide support for their families.Several possible therapeutic approaches are under development that, it is claimed and hoped, may lead to a "cure" for patients with Rett syndrome. While all have a rationale, there are potential obstacles to each being both safe and effective. Furthermore, any strategy that succeeded in restoring normal levels of MECP2 gene expression throughout the brain carries potential pitfalls, so that it will be of crucial importance to introduce any clinical trials of such therapies with great care.Expectations of families for a radical, rational treatment should not be inflated beyond a cautious optimism. This is particularly because affected patients with us now may not be able to reap the full benefits of a "cure". Thus, interventions aimed at enhancing the quality of life of affected patients should not be forgone and their importance should not be minimised.

Indexed as

AnimalsFemaleGene Expression RegulationGenetic TherapyHumansMethyl-CpG-Binding Protein 2MiceRett SyndromeMethyl-CpG-Binding Protein 2CureExpectationsGene editingGene therapyMECP2Quality of lifeRett syndromeSymptomatic treatment

Identifiers

PMID29609636
PMCPMC5879810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.